{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:12:36Z","timestamp":1767139956321,"version":"build-2238731810"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00105-017-4094-1","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T04:51:09Z","timestamp":1513054269000},"page":"58-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Medikament\u00f6se Therapie der Acne inversa","Drug therapy of acne inversa"],"prefix":"10.1007","volume":"69","author":[{"given":"S.","family":"Schneider-Burrus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Arpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Stavermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kokolakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"issue":"Suppl 5","key":"4094_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1610-0387.2012.08006.x","volume":"10","author":"CC Zouboulis","year":"2012","unstructured":"Zouboulis CC, Bechara FG, Fritz K et al (2012) S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa * (number ICD-10 L73.2). J\u00a0Dtsch Dermatol Ges 10(Suppl 5):S1\u2013S31","journal-title":"J Dtsch Dermatol Ges"},{"key":"4094_CR2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L et\u00a0al (2015) European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J\u00a0Eur Acad Dermatol Venereol 29:619\u2013644","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4094_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-017-4082-5","author":"R Sabat","year":"2017","unstructured":"Sabat R, Tsaousi A, Rossbacher J et\u00a0al (2017) Acne inversa\/hidradenitis suppurativa: an update. Hautarzt. \n                        https:\/\/doi.org\/10.1007\/s00105-017-4082-5","journal-title":"Hautarzt"},{"key":"4094_CR4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","volume":"22","author":"OJ Clemmensen","year":"1983","unstructured":"Clemmensen OJ (1983) Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 22:325\u2013328","journal-title":"Int J Dermatol"},{"key":"4094_CR5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","volume":"39","author":"GB Jemec","year":"1998","unstructured":"Jemec GB, Wendelboe P (1998) Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J\u00a0Am Acad Dermatol 39:971\u2013974","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00042728-200802000-00012","volume":"34","author":"MG Buimer","year":"2008","unstructured":"Buimer MG, Ankersmit MF, Wobbes T, Klinkenbijl JH (2008) Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: a\u00a0prospective randomized study. Dermatol Surg 34:224\u2013227","journal-title":"Dermatol Surg"},{"key":"4094_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","volume":"35","author":"J Boer","year":"2010","unstructured":"Boer J, Jemec GB (2010) Resorcinol peels as a\u00a0possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 35:36\u201340","journal-title":"Clin Exp Dermatol"},{"key":"4094_CR8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2016.06.049","volume":"75","author":"PT Riis","year":"2016","unstructured":"Riis PT, Boer J, Prens EP et\u00a0al (2016) Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J\u00a0Am Acad Dermatol 75:1151\u20131155","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaad.2009.12.018","volume":"63","author":"HH Zee van der","year":"2010","unstructured":"van der Zee HH, Prens EP, Boer J (2010) Deroofing: a\u00a0tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J\u00a0Am Acad Dermatol 63:475\u2013480","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR10","doi-asserted-by":"crossref","first-page":"f2121","DOI":"10.1136\/bmj.f2121","volume":"346","author":"F Collier","year":"2013","unstructured":"Collier F, Smith RC, Morton CA (2013) Diagnosis and management of hidradenitis suppurativa. BMJ 346:f2121","journal-title":"BMJ"},{"key":"4094_CR11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2340\/00015555-1841","volume":"94","author":"L Matusiak","year":"2014","unstructured":"Matusiak L, Bieniek A, Szepietowski JC (2014) Bacteriology of hidradenitis suppurativa \u2013 which antibiotics are the treatment of choice? Acta Derm Venereol 94:699\u2013702","journal-title":"Acta Derm Venereol"},{"key":"4094_CR12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","volume":"219","author":"G Gener","year":"2009","unstructured":"Gener G, Canoui-Poitrine F, Revuz JE et al (2009) Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a\u00a0series of 116 consecutive patients. Dermatology (Basel) 219:148\u2013154","journal-title":"Dermatology (Basel)"},{"key":"4094_CR13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","volume":"154","author":"CO Mendonca","year":"2006","unstructured":"Mendonca CO, Griffiths CE (2006) Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 154:977\u2013978","journal-title":"Br J Dermatol"},{"key":"4094_CR14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","volume":"219","author":"HH Zee van der","year":"2009","unstructured":"van der Zee HH, Boer J, Prens EP, Jemec GB (2009) The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology (Basel) 219:143\u2013147","journal-title":"Dermatology (Basel)"},{"key":"4094_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdv.12127","volume":"28","author":"V Bettoli","year":"2014","unstructured":"Bettoli V, Zauli S, Borghi A et al (2014) Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a\u00a0prospective study on 23 patients. J\u00a0Eur Acad Dermatol Venereol 28:125\u2013126","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4094_CR16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/ced.12933","volume":"41","author":"C Dessinioti","year":"2016","unstructured":"Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C (2016) Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a\u00a0prospective study and 1\u2011year follow-up. Clin Exp Dermatol 41:852\u2013857","journal-title":"Clin Exp Dermatol"},{"key":"4094_CR17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000321716","volume":"222","author":"O Join-Lambert","year":"2011","unstructured":"Join-Lambert O, Coignard H, Jais JP et al (2011) Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology (Basel) 222:49\u201358","journal-title":"Dermatology (Basel)"},{"key":"4094_CR18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/09546630600830588","volume":"17","author":"MR Kaur","year":"2006","unstructured":"Kaur MR, Lewis HM (2006) Hidradenitis suppurativa treated with dapsone: a case series of five patients. J\u00a0Dermatolog Treat 17:211\u2013213","journal-title":"J Dermatolog Treat"},{"key":"4094_CR19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000329023","volume":"222","author":"S Yazdanyar","year":"2011","unstructured":"Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GB (2011) Dapsone therapy for hidradenitis suppurativa: a\u00a0series of 24 patients. Dermatology (Basel) 222:342\u2013346","journal-title":"Dermatology (Basel)"},{"key":"4094_CR20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","volume":"186","author":"K Wolk","year":"2011","unstructured":"Wolk K, Warszawska K, Hoeflich C et al (2011) Deficiency of IL-22 contributes to a\u00a0chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J\u00a0Immunol 186:1228\u20131239","journal-title":"J Immunol"},{"key":"4094_CR21","doi-asserted-by":"publisher","first-page":"4097574","DOI":"10.1155\/2016\/4097574","volume":"2016","author":"A Tsaousi","year":"2016","unstructured":"Tsaousi A, Witte E, Witte K et\u00a0al (2016) MMP8 is increased in lesions and blood of acne inversa patients: a potential link to skin destruction and metabolic alterations. Mediators Inflamm 2016:4097574. \n                        https:\/\/doi.org\/10.1155\/2016\/4097574","journal-title":"Mediators Inflamm."},{"issue":"5","key":"4094_CR22","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/bjd.15424","volume":"177","author":"K Wolk","year":"2017","unstructured":"Wolk K, Wenzel J, Tsaousi A et al (2017) Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa\/hidradenitis suppurativa. Br J Dermatol 177(5):1385\u20131393. \n                        https:\/\/doi.org\/10.1111\/bjd.15424","journal-title":"Br J Dermatol"},{"key":"4094_CR23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA (2010) Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a\u00a0randomized, double-blind, placebo-controlled crossover trial. J\u00a0Am Acad Dermatol 62:205\u2013217","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR24","doi-asserted-by":"publisher","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB (2016) Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 375(5):422\u2013434. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1504370","DOI":"10.1056\/NEJMoa1504370"},{"key":"4094_CR25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","volume":"174","author":"JL Blok","year":"2016","unstructured":"Blok JL, Li K, Brodmerkel C et\u00a0al (2016) Ustekinumab in hidradenitis suppurativa: clinical results and a\u00a0search for potential biomarkers in serum. Br J Dermatol 174:839\u2013846","journal-title":"Br J Dermatol"},{"key":"4094_CR26","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","volume":"29","author":"A Nast","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod AD et al (2015) European S3-Guidelines on the systemic treatment of psoriasis vulgaris \u2013 Update 2015 \u2013 Short version \u2013 EDF in cooperation with EADV and IPC. J\u00a0Eur Acad Dermatol Venereol 29:2277\u20132294","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4094_CR27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00105-016-3812-4","volume":"67","author":"S Philipp","year":"2016","unstructured":"Philipp S, Kokolakis G, Sabat R (2016) Systemic treatments for psoriasis and psoriatic arthritis. Hautarzt 67:464\u2013471","journal-title":"Hautarzt"},{"key":"4094_CR28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S et\u00a0al (2016) Safety and efficacy of Anakinra in severe hidradenitis suppurativa: a randomized clinical trial. Jama Dermatol 152:52\u201359","journal-title":"Jama Dermatol"},{"key":"4094_CR29","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2794","author":"A Schuch","year":"2017","unstructured":"Schuch A, Fischer T, Boehner A, Biedermann T, Volz T (2017) Successful treatment of severe recalcitrant Hidradenitis Suppurativa with the Interleukin-17A antibody Secukinumab. Acta Derm Venereol. \n                        https:\/\/doi.org\/10.2340\/00015555-2794","journal-title":"Acta Derm Venereol"},{"key":"4094_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15769","author":"L Thorlacius","year":"2017","unstructured":"Thorlacius L, Theut Riis P, Jemec GBE (2017) Severe hidradenitis suppurativa responding to treatment with secukinumab: a\u00a0case report. Br J Dermatol. \n                        https:\/\/doi.org\/10.1111\/bjd.15769","journal-title":"Br J Dermatol"},{"key":"4094_CR31","first-page":"513","volume":"6","author":"K Dredge","year":"2005","unstructured":"Dredge K (2005) CC-1088 celgene. Curr Opin Investig Drugs 6:513\u2013517","journal-title":"Curr Opin Investig Drugs"},{"key":"4094_CR32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","volume":"76","author":"P Weber","year":"2017","unstructured":"Weber P, Seyed Jafari SM, Yawalkar N, Hunger RE (2017) Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients. J\u00a0Am Acad Dermatol 76:1189\u20131191","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s13671-013-0064-8","volume":"3","author":"I Deckers","year":"2014","unstructured":"Deckers I, van der Zee H, Prens E (2014) Epidemiology of Hidradenitis Suppurativa: prevalence, pathogenesis, and factors associated with the development of HS. Curr Dermatol Rep 3:54\u201360. \n                        https:\/\/doi.org\/10.1007\/s13671-013-0064-8","journal-title":"Curr Dermatol Rep"},{"key":"4094_CR34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11154-016-9366-z","volume":"17","author":"I Karagiannidis","year":"2016","unstructured":"Karagiannidis I, Nikolakis G, Sabat R, Zouboulis CC (2016) Hidradenitis suppurativa\/acne inversa: an endocrine skin disorder? Rev Endocr Metab Disord 17:335\u2013341","journal-title":"Rev Endocr Metab Disord"},{"key":"4094_CR35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","volume":"23","author":"J Revuz","year":"2009","unstructured":"Revuz J (2009) Hidradenitis suppurativa. J\u00a0Eur Acad Dermatol Venereol 23:985\u2013998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4094_CR36","first-page":"1138","volume":"141","author":"AM Farrell","year":"1999","unstructured":"Farrell AM, Randall VA, Vafaee T, Dawber RP (1999) Finasteride as a\u00a0therapy for hidradenitis suppurativa. Br J Dermatol 141:1138\u20131139","journal-title":"Br J Dermatol"},{"key":"4094_CR37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/09546630510031403","volume":"16","author":"MA Joseph","year":"2005","unstructured":"Joseph MA, Jayaseelan E, Ganapathi B, Stephen J (2005) Hidradenitis suppurativa treated with finasteride. J\u00a0Dermatolog Treat 16:75\u201378","journal-title":"J Dermatolog Treat"},{"key":"4094_CR38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.1986.tb05741.x","volume":"115","author":"RS Sawers","year":"1986","unstructured":"Sawers RS, Randall VA, Ebling FJ (1986) Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol 115:269\u2013274","journal-title":"Br J Dermatol"},{"key":"4094_CR39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","volume":"115","author":"PS Mortimer","year":"1986","unstructured":"Mortimer PS, Dawber RP, Gales MA, Moore RA (1986) A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 115:263\u2013268","journal-title":"Br J Dermatol"},{"key":"4094_CR40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bmj.298.6665.28","volume":"298","author":"AJ Stellon","year":"1989","unstructured":"Stellon AJ, Wakeling M (1989) Hidradenitis suppurativa associated with use of oral contraceptives. BMJ 298:28\u201329","journal-title":"BMJ"},{"key":"4094_CR41","first-page":"22","volume":"7","author":"SB Nickle","year":"2014","unstructured":"Nickle SB, Peterson N, Peterson M (2014) Updated physician\u2019s guide to the off-label uses of oral isotretinoin. J\u00a0Clin Aesthet Dermatol 7:22\u201334","journal-title":"J Clin Aesthet Dermatol"},{"key":"4094_CR42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000182261","volume":"218","author":"A Soria","year":"2009","unstructured":"Soria A, Canoui-Poitrine F, Wolkenstein P et al (2009) Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a\u00a0retrospective study based on patients\u2019 outcome assessment. Dermatology (Basel) 218:134\u2013135","journal-title":"Dermatology (Basel)"},{"key":"4094_CR43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0190-9622(99)70530-X","volume":"40","author":"J Boer","year":"1999","unstructured":"Boer J, van Gemert MJ (1999) Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J\u00a0Am Acad Dermatol 40:73\u201376","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjd.12884","volume":"171","author":"L Matusiak","year":"2014","unstructured":"Matusiak L, Bieniek A, Szepietowski JC (2014) Acitretin treatment for hidradenitis suppurativa: a\u00a0prospective series of 17 patients. Br J Dermatol 171:170\u2013174","journal-title":"Br J Dermatol"},{"key":"4094_CR45","first-page":"155","volume":"150","author":"R Verdolini","year":"2015","unstructured":"Verdolini R, Simonacci F, Menon S, Pavlou P, Alitretinoin MB (2015) a\u00a0useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G\u00a0Ital Dermatol Venereol 150:155\u2013162","journal-title":"G Ital Dermatol Venereol"},{"key":"4094_CR46","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/j.jaad.2012.06.011","volume":"67","author":"L Bianchi","year":"2012","unstructured":"Bianchi L, Hansel K, Stingeni L (2012) Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A. J\u00a0Am Acad Dermatol 67:e278\u2013279","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR47","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2230.2002.11125.x","volume":"27","author":"GB Jemec","year":"2002","unstructured":"Jemec GB (2002) Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol 27:528\u2013529","journal-title":"Clin Exp Dermatol"},{"key":"4094_CR48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000332846","volume":"223","author":"HH Zee van der","year":"2011","unstructured":"van der Zee HH, Prens EP (2011) The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology (Basel) 223:169\u2013173","journal-title":"Dermatology (Basel)"},{"key":"4094_CR49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000100883","volume":"214","author":"A Brocard","year":"2007","unstructured":"Brocard A, Knol AC, Khammari A, Dreno B (2007) Hidradenitis suppurativa and zinc: a\u00a0new therapeutic approach. A pilot study. Dermatology (Basel) 214:325\u2013327","journal-title":"Dermatology (Basel)"},{"key":"4094_CR50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.08.010","volume":"84","author":"S Hessam","year":"2016","unstructured":"Hessam S, Sand M, Meier NM et al (2016) Combination of oral zinc gluconate and topical triclosan: an anti-inflammatory treatment modality for initial hidradenitis suppurativa. J\u00a0Dermatol Sci 84:197\u2013202","journal-title":"J Dermatol Sci"},{"key":"4094_CR51","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","volume":"27","author":"R Verdolini","year":"2013","unstructured":"Verdolini R, Clayton N, Smith A, Alwash N, Mannello B (2013) Metformin for the treatment of hidradenitis suppurativa: a\u00a0little help along the way. J\u00a0Eur Acad Dermatol Venereol 27:1101\u20131108","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4094_CR52","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaad.2013.11.014","volume":"70","author":"DA Gold","year":"2014","unstructured":"Gold DA, Reeder VJ, Mahan MG, Hamzavi IH (2014) The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J\u00a0Am Acad Dermatol 70:699\u2013703","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/09546634.2013.800184","volume":"25","author":"V Lernia Di","year":"2014","unstructured":"Di Lernia V, Ricci C, Lallas A, Ficarelli E (2014) Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a\u00a0retrospective study. J\u00a0Dermatolog Treat 25:73\u201374","journal-title":"J Dermatolog Treat"},{"key":"4094_CR54","doi-asserted-by":"crossref","first-page":"e31810","DOI":"10.1371\/journal.pone.0031810","volume":"7","author":"R Sabat","year":"2012","unstructured":"Sabat R, Chanwangpong A, Schneider-Burrus S et al (2012) Increased prevalence of metabolic syndrome in patients with acne inversa. PLOS ONE 7:e31810","journal-title":"PLOS ONE"},{"key":"4094_CR55","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1468-3083.2000.00087.x","volume":"14","author":"JM Werth von der","year":"2000","unstructured":"von der Werth JM, von der Williams HC (2000) The natural history of hidradenitis suppurativa. J\u00a0Eur Acad Dermatol Venereol 14:389\u2013392","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4094_CR56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-0625.2012.01443.x","volume":"21","author":"K Winter de","year":"2012","unstructured":"de Winter K, van der Zee HH, Prens EP (2012) Is mechanical stress an important pathogenic factor in hidradenitis suppurativa? Exp Dermatol 21:176\u2013177","journal-title":"Exp Dermatol"},{"key":"4094_CR57","first-page":"743","volume":"11","author":"A Kurek","year":"2013","unstructured":"Kurek A, Peters JEM, Sabat R, Sterry W, Schneider-Burrus S (2013) Depression is a\u00a0frequent co-morbidity in patients with acne inversa. J\u00a0Dtsch Dermatol Ges 11:743\u2013749 (Seite 743\u2013750)","journal-title":"J Dtsch Dermatol Ges"},{"key":"4094_CR58","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaad.2011.10.024","volume":"67","author":"A Kurek","year":"2012","unstructured":"Kurek A, Peters EM, Chanwangpong A et\u00a0al (2012) Profound disturbances of sexual health in patients with acne inversa. J\u00a0Am Acad Dermatol 67:422\u2013428, 428.e1","journal-title":"J Am Acad Dermatol"},{"key":"4094_CR59","doi-asserted-by":"publisher","first-page":"S0022-202X(17)3","DOI":"10.1016\/j.jid.2017.09.008","volume":"pii","author":"L Thorlacius","year":"2017","unstructured":"Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A (2017) Increased suicide risk in patients with Hidradenitis Suppurativa. J\u00a0Invest Dermatol pii: S0022-202X(17)32955-X. \n                        https:\/\/doi.org\/10.1016\/j.jid.2017.09.008","journal-title":"J Invest Dermatol"}],"updated-by":[{"DOI":"10.1007\/s00105-018-4149-y","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000}}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-017-4094-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4094-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4094-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T11:31:39Z","timestamp":1515583899000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-017-4094-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["4094"],"URL":"https:\/\/doi.org\/10.1007\/s00105-017-4094-1","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]}}}